Sue Chua

669 total citations
21 papers, 369 citations indexed

About

Sue Chua is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Sue Chua has authored 21 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Sue Chua's work include Medical Imaging Techniques and Applications (8 papers), Radiomics and Machine Learning in Medical Imaging (7 papers) and Prostate Cancer Treatment and Research (7 papers). Sue Chua is often cited by papers focused on Medical Imaging Techniques and Applications (8 papers), Radiomics and Machine Learning in Medical Imaging (7 papers) and Prostate Cancer Treatment and Research (7 papers). Sue Chua collaborates with scholars based in United Kingdom, Australia and Canada. Sue Chua's co-authors include Gary Cook, Gopinath Gnanasegaran, Chris Parker, Anne-Kirsti Aksnes, Bernadette Johnson, Valerie Lewington, Ian Chau, Henry Tam, David Cunningham and Stephen Johnston and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Sue Chua

20 papers receiving 366 citations

Peers

Countries citing papers authored by Sue Chua

Since Specialization

Citations

This map shows the geographic impact of Sue Chua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sue Chua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sue Chua more than expected).

Fields of papers citing papers by Sue Chua

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sue Chua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sue Chua. The network helps show where Sue Chua may publish in the future.

Co-authorship network of co-authors of Sue Chua

This figure shows the co-authorship network connecting the top 25 collaborators of Sue Chua. A scholar is included among the top collaborators of Sue Chua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sue Chua. Sue Chua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The role of PET/CT in peripheral T‐cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO‐T trial 2025 ·British Journal of Haematology ·Mary Gleeson, (unknown), David Cunningham, Clare Peckitt, Karen Thomas, Yong Du, (unknown), (unknown), Hui Cheng Chen, Sanjay S. Patel, Ian Chau, Peter Johnson, Andrew Wotherspoon, Ayoma D. Attygalle, Eliza A. Hawkes, Mac Macheta, Graham P. Collins, Kate Cwynarski, Sue Chua	0
2	Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial 2023 ·Cancer Imaging ·Samuel Tremblay, (unknown), Andrew Weickhardt, Ian D. Davis, Andrew M. Scott, Rodney J. Hicks, Ur Metser, Sue Chua, (unknown), Shonit Punwani, Heather Payne, Nina Tunariu, Bao Ho, (unknown), (unknown), Glenn Bauman, Louise Emmett, Frédéric Pouliot	1
3	Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response 2023 ·JNCI Cancer Spectrum ·Chris Parker, Nina Tunariu, Holly Tovey, Roberto Alonzi, Matthew Blackledge, Gary Cook, Sue Chua, Yong Du, S. Hafeez, Iain Murray, Anwar R. Padhani, John Staffurth, Alison Tree, (unknown), (unknown), Andra Curcean, Peter Chatfield, Sophie Perry, Dow‐Mu Koh, Emma Hall	3
4	The Diagnostic Accuracy of 18F-FGD-PET/CT for Cancer of the Gallbladder: A Retrospective Study 2022 ·SHILAP Revista de lepidopterología ·Stephanos Pericleous, (unknown), Andrew Wotherspoon, Monica Terlizzo, Angela M. Riddell, Gina Brown, Joshua Shur, Sue Chua, (unknown), Nicos Middleton, David Cunningham, (unknown), Ricky H. Bhogal	4
5	UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging 2019 ·Nuclear Medicine Communications ·Asim Afaq, Fergus Gleeson, Andrew Scarsbrook, Kevin M. Bradley, Manil Subesinghe, Ruth E. Macpherson, Athar Haroon, Neel Patel, Sue Chua, Wai‐Lup Wong, Sobhan Vinjamuri, Victoria Warbey, Gary Cook, Jamshed Bomanji	7
6	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer 2019 ·JAMA Oncology ·Gerhardt Attard, Axel S. Merseburger, Wiebke Arlt, Cora N. Sternberg, Susan Feyerabend, Alfredo Berruti, Steven Joniau, Lajos Géczi, Florence Lefresne, Marjolein Lahaye, (unknown), (unknown), Sue Chua, Robert J. Jones, Bertrand Tombal	35
7	Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients 2018 ·European Journal of Nuclear Medicine and Molecular Imaging ·Mubarik Arshad, Andrew Thornton, Haonan Lu, Henry Tam, (unknown), (unknown), Andrew Scarsbrook, Garry McDermott, Gary Cook, David Landau, Sue Chua, Richard A. O’Connor, Jeanette Dickson, Danielle Power, Tara Barwick, Andrea Rockall, Eric O. Aboagye	53
8	Impact of 18 F-fluciclovine PET/CT on Clinical Management of Patients with Recurrent Prostate Cancer: Results from the Phase 3 FALCON Trial 2017 ·International Journal of Radiation OncologyBiologyPhysics ·Eugene Teoh, David Bottomley, Andrew Scarsbrook, Heather Payne, Asim Afaq, (unknown), N. van As, Sue Chua, Peter Hoskin, Anthony L. Chambers, Gary Cook, Victoria Warbey, Albert Chau, Penelope Ward, (unknown), Daniel Stevens, L.D. Wilson, Fergus Gleeson	5
9	Metabolic Tumor Volume Changes Measured by 18F-FDG-PET/CT After 1 Cycle of Induction Chemotherapy Is an Early Predictor of Radical Chemoradiation Therapy Outcome in Head and Neck Squamous Cell Carcinoma 2016 ·International Journal of Radiation OncologyBiologyPhysics ·Kee H. Wong, Liam Welsh, Dualta Mcquaid, Alex Dunlop, Iain Murray, Yong Du, Sue Chua, Rafał Panek, Angela M. Riddell, Dow‐Mu Koh, (unknown), (unknown), Kevin J. Harrington, K. Newbold	2
10	Objective comparison of lesion detectability in low and medium-energy collimator iodine-123 mIBG images using a channelized Hotelling observer 2016 ·Physics in Medicine and Biology ·Rebecca Gregory, Iain Murray, Jonathan Gear, Matthew Aldridge, Daniel S. Levine, (unknown), Wendy A. Waddington, Sue Chua, Glenn Flux	1
11	The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis 2015 ·Clinical Nuclear Medicine ·Henry Tam, Gary Cook, Ian Chau, (unknown), Imene Zerizer, Yong Du, David Cunningham, Dow‐Mu Koh, Sue Chua	17
12	Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. 2015 ·Journal of Clinical Oncology ·Elizabeth Smyth, Nicholas C. Turner, Clare Peckitt, Alex Pearson, Gina Brown, Sue Chua, Angela Gillbanks, Stephen Johnston, Noelia Tarazona, Ros Cutts, Elaine Kilgour, Claire Rooney, Neil R. Smith, (unknown), Mazhar Ajaz, Anne Thomas, David Watkins, Ian Chau, Sanjay Popat, David Cunningham	37
13	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma 2014 ·European Journal Of Haematology ·Sarah Barton, Eliza A. Hawkes, David Cunningham, Clare Peckitt, Sue Chua, Andrew Wotherspoon, Ayoma D. Attygalle, Alan Horwich, Mike Potter, Mark Ethell, Claire Dearden, Mary Gleeson, Ian Chau	9
14	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma 2013 ·Annals of Hematology ·Eliza A. Hawkes, Sarah Barton, David Cunningham, Clare Peckitt, Sue Chua, Andrew Wotherspoon, Alan Horwich, Mike Potter, (unknown), Claire Dearden, Ian Chau	7
15	The utility of whole-body diffusion-weighted MRI for delineating regions of interest in PET 2012 ·Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment ·Matthew Blackledge, Dow‐Mu Koh, Dave Collins, Sue Chua, Martin O. Leach	3
16	18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) 2011 ·EJNMMI Research ·Gary Cook, Chris Parker, Sue Chua, Bernadette Johnson, Anne-Kirsti Aksnes, Valerie Lewington	91
17	Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom. 2011 ·Journal of Clinical Oncology ·(unknown), Gina Brown, Richard J. Heald, Sue Chua, Gary Cook, Yolanda Barbáchano, Ian Chau, A. Wotherspoon, Diana Tait	18
18	The outcome and significance of mixed metabolic treatment response (MR) on interim 18F-FDG PET/CT in patients with advanced solid tumours treated with novel drugs 2010 ·Sue Chua, Henry Tam, Dow‐Mu Koh, Gary Cook	1
19	Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases 2009 ·Seminars in Nuclear Medicine ·Sue Chua, Gopinath Gnanasegaran, Gary Cook	48
20	A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer 2009 ·British Journal of Cancer ·Robin L. Jones, G. Walsh, S. Ashley, Sue Chua, Rajiv Agarwal, Mary O’Brien, Stephen Johnston, Ian E. Smith	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact